Global Colorectal Cancer Diagnosis & Therapeutics Market to Top $13.6 billion by 2025, Expanding at 4.5% CAGR

Global colorectal cancer diagnosis and therapeutics market was valued at $13.6 billion in 2025 and is growing at a CAGR of 4.5% during the forecast period (2026-2035). Regulatory support through fast-track designations and expedited review pathways plays a key role in driving growth in the global colorectal cancer diagnosis and therapeutics market by enabling faster patient access to novel and effective treatments. Such initiatives encourage the development and adoption of targeted therapies, particularly those addressing specific genetic or molecular tumor profiles. For instance, in November 2025, the FDA granted Fast Track Designation to a new drug combination for metastatic colorectal cancer. This treatment, which includes alnodesertib and a low dose of irinotecan, targets cancer cells lacking the ATM protein, exploiting their inability to repair DNA damage. Clinical trial results showed a significant reduction in tumor size among patients with ATM-deficient tumors receiving this therapy.

Browse the full report description of “Colorectal Cancer Diagnosis and Therapeutics Market Size, Share & Trends Analysis by Type (Adenocarcinomas, Carcinoid Tumors, Lymphomas, Sarcomas, and Gastrointestinal Stromal Tumors (GISTS)), by Diagnosis (Digital Rectal Examination, Fecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, and Others (Biopsy)), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Multispecialty Hospitals, and Cancer Research Centers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/colorectal-cancer-therapeutics-market

Leading Innovators Shaping the Future of Colorectal Cancer Diagnosis and Treatment

The key players in the colorectal cancer diagnosis and therapeutics market include Amgen Inc., Bristol Myers Squibb (BMS), Eli Lilly and Co., Hoffmann-La Roche AG, Merck & Co., Inc., among others. These companies are driving innovation in digital health solutions such as telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, shaping the future of healthcare delivery globally.

• In February 2025, Amgen's combination therapy of Lumakras (sotorasib) and Vectibix (panitumumab) was approved by the FDA for treating metastatic colorectal cancer in patients with the KRAS G12C mutation. This therapy provides a new option for patients whose cancer has worsened despite previous chemotherapy and marks a significant advance in precision medicine for challenging mutations, potentially improving outcomes for patients with few treatment alternatives.
• In August 2025, the FDA approved the Agilent MMR IHC Panel pharmDx as the first companion diagnostic for colorectal cancer, designed to identify mismatch repair deficient (dMMR) tumors. This panel aids in guiding immunotherapy treatments with nivolumab and ipilimumab, particularly for patients with high mutation rates in their tumors. Accurate detection of dMMR status is essential for optimizing immunotherapy effectiveness, as these tumors respond better to immune checkpoint inhibitors. The approval highlights the significance of biomarkers in treatment personalization, supported by clinical trials demonstrating the efficacy of nivolumab and its combination with ipilimumab in improving patient outcomes.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Diagnosis
  • By Treatment
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Amgen Inc., Bristol Myers Squibb (BMS), Eli Lilly and Co., Hoffmann-La Roche AG, Merck & Co., Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Colorectal Cancer Diagnosis and Therapeutics Market Report Segment

By Type

• Adenocarcinomas
• Carcinoid Tumors
• Lymphomas
• Sarcomas
• Gastrointestinal Stromal Tumors (GISTS)

By Diagnosis

• Digital Rectal Examination
• Fecal Occult Blood Test
• Flexible Sigmoidoscopy
• Colonoscopy
• Others (Biopsy)

By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy

By End-User

• Multispecialty Hospitals
• Cancer Research Centers

Global Colorectal Cancer Diagnosis and Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/colorectal-cancer-therapeutics-market